Michael A.S. Jewett
University Health Network, Princess Margaret Cancer Centre, University of Toronto
Papers
7
Total Citations
76
H-Index
4
About
Dr. Michael A.S. Jewett is a world-renowned urologic oncologist whose research has fundamentally shaped the surgical management of testicular and kidney cancers. A pioneer in minimally invasive surgery, his major contributions center on validating robotic approaches for complex oncologic procedures. His landmark 2021 study on robotic retroperitoneal lymph node dissection (R-RPLND) for testis cancer, cited over 20 times, established a safer, less morbid alternative to traditional open surgery. He further advanced this field with a 2024 propensity-matched analysis demonstrating comparable oncologic outcomes between open and robotic RPLND for clinical stage II disease, a critical finding for evidence-based surgical choice. In renal cancer, Dr. Jewett’s work on achieving the “trifecta” (negative margins, minimal complications, and renal function preservation) in partial nephrectomy has guided surgeons toward optimal outcomes. His investigations into health-related quality of life after robotic versus open prostatectomy have also informed patient counseling. With a career spanning decades, Dr. Jewett remains an authoritative voice in urologic oncology, actively debating clinical dilemmas such as managing small renal masses in solitary kidneys. His research continues to drive the adoption of robotic techniques while rigorously proving their equivalence to gold-standard open surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7